Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Published:2024-01-22 Issue:2 Volume:7 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Fang Kunpeng¹,Wang Jie²,Yuan Jianyong³,Sui Chengjun¹,Zhi Jiajun⁴,Xia Yong⁵,Sun Minmin⁶

Affiliation:

1. Department of Special Treatment I Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai China

2. Department of Hepatic Surgery II Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai China

3. Hepatobiliary Pancreatic Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine Shanghai China

4. Department of Colorectal and Anal Surgery Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

5. Department of Hepatic Surgery IV Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai China

6. Department of Hepatic Surgery I Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai China

Abstract

AbstractObjectiveTo investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.MethodsWe retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.ResultsAll patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.ConclusionsPatients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1952

Reference20 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Outcome of Laparoscopic Versus Open Resection for Transverse Colon Cancer

3. Long-term oncologic outcomes of laparoscopicvsopen surgery for stages II and III rectal cancer: A retrospective cohort study

4. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer

5. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2024-03-23